Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other Non-Current Assets (2022 - 2026)

TriSalus Life Sciences has reported Other Non-Current Assets over the past 5 years, most recently at $69000.0 for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 83.73% year-over-year to $69000.0; the TTM value through Mar 2026 reached $69000.0, down 83.73%, while the annual FY2025 figure was $418000.0, 1.18% down from the prior year.
  • Other Non-Current Assets for Q1 2026 was $69000.0 at TriSalus Life Sciences, down from $418000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $466000.0 in Q4 2023 and troughed at $69000.0 in Q1 2026.
  • A 5-year average of $387000.0 and a median of $421000.0 in 2024 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: increased 26.98% in 2023 and later tumbled 83.73% in 2026.
  • Year by year, Other Non-Current Assets stood at $367000.0 in 2022, then rose by 26.98% to $466000.0 in 2023, then decreased by 9.23% to $423000.0 in 2024, then decreased by 1.18% to $418000.0 in 2025, then plummeted by 83.49% to $69000.0 in 2026.
  • Business Quant data shows Other Non-Current Assets for TLSI at $69000.0 in Q1 2026, $418000.0 in Q4 2025, and $419000.0 in Q3 2025.